Thalys(SH:603716) Cai Jing Wang·2025-09-29 12:08Core Viewpoint - The company is focusing on transforming its traditional medical supply chain services into intelligent medical solutions while balancing short-term losses with long-term strategic goals [1] Group 1: Strategic Initiatives - The company is strategically positioning itself in the automated upgrade track of the microbiological testing field, collaborating with COPAN to introduce the first domestic AI recognition system for microbiology [1] - The company has launched a domestically registered microbiological sample preprocessing system, WASP-XPS, in response to the "Made in China" initiative, aiming to enhance its competitive edge against international brands [1] Group 2: Collaborative Projects - In early 2025, the company will collaborate with Shanghai Huashan Hospital and other institutions to establish an "Automated Drug Sensitivity Testing Platform + Intelligent AI Model Drug Sensitivity Diagnosis System" [1] Group 3: R&D Progress - The company is advancing its therapeutic hypertension vaccine, HJY-ATRQβ-001, which is recognized as a national Class I innovative biological drug and is set to enter clinical research by May 28, 2025 [1] - The vaccine aims to provide long-lasting and stable blood pressure control, addressing the limitations of traditional oral medications that require daily administration [1] - The company is also exploring other therapeutic vaccines targeting hypertension, hyperlipidemia, type 2 diabetes, and obesity, which have completed preclinical conceptual validation [1]